Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07673367 · ClinicalTrials.gov registry record · Phase 2
Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma
A Phase 2 study, sponsored by Vanderbilt-Ingram Cancer Center.
- Not yet
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT07673367: Clinical Trial Phase 2 study, sponsored by Vanderbilt-Ingram Cancer Center.
NCT07673367 is a Phase 2 study that has not yet begun recruiting, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 25 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07673367, a Phase 2 study, has not yet begun recruiting, sponsored by Vanderbilt-Ingram Cancer Center.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
This phase II trial tests the effect of nemtabrutinib in combination with brexucabtagene autoleucel (brexu-cel) in treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Nemtabrutinib, a BTK inhibitor, may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chimeric antigen receptor (CAR) T-cell therapy, such as brexu-cel, is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a CAR. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Chemotherapy, such as fludarabine and cyclophosphamide, are given before CAR T cell therapy to help kill cancer cells in the body and help make room for the CAR T cells. Giving nemtabrutinib in combination with brexu-cel may be safe, tolerable, and/or effective in treating patients with relapsed or refractory mantle cell lymphoma.
Primary Outcome
Will be analyzed using Kaplan-Meier product limit methods to estimate the survival distribution, median time-to-event with 95% confidence interval, patients at risk, patients with an event, patients censored and survival probabilities at selected time points. Kaplan-Meier methods will be used to estimate the event-free curves and corresponding quartiles (including the median).
Interventions
- DRUG Nemtabrutinib
- DRUG Brexucabtagene autoleucel ( other names: brexu-cel , Tecartus)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2026-07-31 |
| Est. Completion | 2032-07-31 |
| Phase | Phase 2 |
What is known before NCT07673367 opens enrollment
NCT07673367 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 2 interventions - of which Nemtabrutinib is the first listed.
NCT07673367 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07673367 about?
NCT07673367 is a clinical study titled "Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma". This phase II trial tests the effect of nemtabrutinib in combination with brexucabtagene autoleucel (brexu-cel) in treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Nemtabrutinib, a BT...
What is the current status of trial NCT07673367?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2026-07-31. Estimated completion is 2032-07-31.
What interventions are being tested in trial NCT07673367?
The interventions under investigation include: Nemtabrutinib (DRUG), Brexucabtagene autoleucel ( other names: brexu-cel , Tecartus) (DRUG).
Who is sponsoring clinical trial NCT07673367?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07673367's enrollment target sits among peer trials
25 1719th of 2000 higher than 245 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI